Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention and treatment of kidney transplantation rejection by innovative therapeutic apheresis
2008-007047-13Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in kidney allograft rejection, end-stage kidney disease (ESKD) and HLA sensitization (2 arms), sponsored by IRCCS San Matteo Foundation. Started Mar 2009; status: completed.
02
Drugs
rituximab
03
Conditions
kidney allograft rejectionend-stage kidney disease (ESKD)HLA sensitization
Beyond the preview
Go deeper on 2008-007047-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007047-13.